Budesonide

BOSTON — Patients with mild asthma lowered their severe exacerbation risk by almost half by using as-needed albuterol-budesonide, according to data presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Patients with COPD faced a decreased risk of severe cardiopulmonary events if treated with single inhaler vs. multiple inhaler triple therapy, according to data presented at the CHEST Annual Meeting.

Tofacitinib “should be considered as a treatment option” for patients with refractory celiac disease type 2 who previously failed treatment with therapies such as budesonide, according to data in Clinical Gastroenterology and Hepatology.

SAN DIEGO — Patients with COPD on budesonide/glycopyrrolate/formoterol fumarate had a lower risk for cardiopulmonary outcomes, according to research presented at the American Thoracic Society International Conference.

Due to misleading claims in a sales aid for Breztri Aerosphere, a triple inhaled therapy for COPD, the FDA has issued a warning letter to its manufacturer, AstraZeneca.

WASHINGTON — Patients with COPD on budesonide/glycopyrrolate/formoterol fumarate within 30 days of an exacerbation had fewer future exacerbations, according to data presented at the American Thoracic Society International Conference.

WASHINGTON — Compared with dual therapies, a triple fixed-dose combination budesonide/glycopyrrolate/formoterol fumarate metered-dose inhaler showed more reductions in exacerbation rates across different COPD severity levels.

Padagis received FDA approval of its abbreviated new drug application for budesonide 2mg rectal foam for the induction of remission in patients with mild to moderate ulcerative colitis, according to a manufacturer release.

Early treatment with oral fluvoxamine plus inhaled budesonide reduced the incidence of progression to severe disease among high-risk outpatients with COVID-19, according to research published in Annals of Internal Medicine.